On October 2nd, Andrew Hutchinson, External Research & Scouting Lead for Alexion Pharmaceuticals, provided his insights on the strategic partnering process between early stage therapeutic companies and big pharma to the OBIO community.
Andrew placed strong emphasis on the difference between an investor deck and a partnering deck. The two have a very different purpose (and audience), and thus should be structured differently.
Download the Blog here